NASDAQ:ACET

Adicet Bio Stock News

Healthcare > Biotechnology

Buy ACET

*Your capital is at risk

$9.11

+0.0500 (+0.552%)

At Close: Jul 31, 2026

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

07:00am, Thursday, 19'th Sep 2024

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun

UL Solutions Warns of Potentially Hazardous Communications Cable

07:13pm, Friday, 30'th Aug 2024

NORTHBROOK, Ill.--(BUSINESS WIRE)--The following is a notification from UL Solutions that the communications cable that bears the serial numbers identified below may pose a potential fire hazard. The

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05:44pm, Friday, 30'th Aug 2024

Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag

10:56am, Tuesday, 09'th Jul 2024

Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.

3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns

05:05pm, Tuesday, 02'nd Jul 2024

One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering.

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma

07:00am, Monday, 24'th Jun 2024

Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024

07:22pm, Monday, 10'th Jun 2024

Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally.